SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is buzzing due to recent industry discussions highlighting advanced optical networking for AI and related strategic acquisitions, sparking speculation about its patented interposer technology. The community is intensely focused on POET's platform as a game-changer for hyperscale data centers, citing its efficiency and numerous partnerships with major industry players. Amidst a quiet period from management, investors are keenly anticipating news that could solidify its position at the forefront of the photonics revolution.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after receiving positive FDA feedback, which significantly de-risks the regulatory pathway for sonelokimab in hidradenitis suppurativa by allowing reliance on existing trial data for BLA submission. This development has fueled widespread community speculation around potential acquisition bids from major pharmaceutical companies like Merck and Eli Lilly, intensifying discussions about the drug's long-term value and multi-indication potential.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is trending amid strong market interest in edge computing solutions for the defense sector, recently bolstered by a new pre-production order from a major U.S. defense contractor. The community is buzzing with anticipation for a much larger situational awareness system contract, viewing the company as a key player in a rapidly expanding industry with a low share float.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company is trending with significant bullish momentum, fueled by strong community sentiment surrounding its role in the U.S. critical minerals and battery recycling sector. Investors are actively discussing the impact of rising lithium prices and the company's strategic positioning amidst government initiatives like the G7 summit on critical metals, anticipating future growth and potential project milestones. Many believe ABAT is poised for substantial appreciation as demand for domestic battery materials heats up.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is garnering significant attention amid heightened geopolitical interest in Greenland's rare earth deposits, driven by discussions around U.S. national security and securing critical mineral supply chains. The community is buzzing about upcoming high-level meetings between U.S., Danish, and Greenlandic officials, with many speculating on potential U.S. access to these strategic resources and anticipating a substantial upside for CRML's Tanbreez project. Despite recent volatility, investors are actively buying dips, holding strong conviction that CRML, with its large heavy rare earth element deposits, is a key player in reducing Western reliance on foreign suppliers.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as geopolitical tensions, notably around Venezuela, fuel community debate over potential market volatility, with many anticipating a significant spike amidst broader economic concerns like debt and an AI bubble. Despite overall market resilience, traders are sharply divided, actively discussing hedging strategies and drawing parallels to past market crashes, even as others caution against the ETF's inherent decay.

Lulu's Fashion Lounge Holdings, Inc. engages in providing an online website for clothing. It offers retailing of women's clothing, shoes, and accessories. The company was founded in 1996 and is headquartered in Chico, CA.

Lulus Fashion Lounge Holdings Inc

Lulu's Fashion Lounge Holdings (LVLU) is generating significant buzz and volume after Friedland Enterprises disclosed a substantial stake, pushing for immediate governance reforms. The community is heavily discussing Friedland's strong belief that the stock is profoundly undervalued compared to its peers, citing a considerable valuation gap. This activist involvement and proposed operational improvements are driving widespread speculation about the company's potential for a major re-rating and sustained price movement.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor (TSM) is trending due to reports of an impending US-Taiwan trade agreement that could significantly expand its manufacturing presence in Arizona, alongside robust revenue growth and optimistic analyst upgrades. The community is actively discussing TSM's critical role as the backbone of the AI sector, driven by surging chip demand and its strategic advancements in packaging capacity amid evolving geopolitical considerations.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix (BDSX) is trending after releasing strong preliminary fourth quarter and full-year 2025 results, which reported significant revenue growth and reaffirmed Adjusted EBITDA positivity. This announcement has ignited massive trading volume and a sharp increase in share price, leading to community discussion around a potential short squeeze and significant upside, alongside concerns about future dilution risks.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending due to contrasting reactions following its latest earnings report, which highlighted robust growth in automotive and AI initiatives but also included a significant one-time tax-related charge. This has fueled a divided community sentiment, with many questioning the stock's market performance despite positive operational news amidst ongoing discussions about smartphone market competition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>iBio intends to use the proceeds from the private placement toward advancing its preclinical cardiometabolic programs.</li><li>This includes the IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs.</li><li>The company also stated that it will use the funds to continue to progress other preclinical assets in the pipeline.</li></ul>Shares of iBio Inc. (IBIO) surged more than 12% in Friday’s pre-market trade after the company announced a private placement of securities worth $26 million.In its announcement, iBio stated that it has entered into a securities purchase agreement with existing healthcare-focused, high-quality institutional investors for private placement financing. It expects the offering to close on or about Jan. 13, 2026, subject to customary closing conditions.iBio stated that it is selling more than 11 million shares of its common stock at a purchase price of $2.35 apiece.<h2 class="st-heading-2">Here’s What iBio Intends To Use Funds For</h2>In its announcement, iBio noted that it intends to use the proceeds from the private placement toward advancing its preclinical cardiometabolic programs. This includes the IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs.Additionally, iBio said it will use the funds to advance other preclinical assets in the pipeline. The balance, if any, would be used toward meeting the company’s working capital requirements, iBio stated.The company added that the $26 million private placement extends its cash runway into 2028. It is also worth nearly 50% of iBio’s current market capitalization, which stood at nearly $53 million on Thursday.<h2 class="st-heading-2">What Does iBio Do?</h2>iBio is a San Diego, California-based company that is working on the development of cardiometabolic and obesity medicines to promote higher quality weight loss and enhance overall metabolic health and function.The company states that current GLP-1 treatments result in muscle loss in addition to fat loss. However, its therapeutic candidates for cardiometabolic diseases and obesity aim to preserve and build muscle mass during weight loss.iBio says it uses its patented artificial intelligence and machine learning platform to accelerate the discovery of novel therapies for obesity and cardiometabolic disorders.<h2 class="st-heading-2">Here’s What Stocktwits Users Think</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/IBIO">iBio</a> trended in the ‘neutral’ territory at the time of writing.One user on the platform stated that the private placement is “bullish” news for the company, and that the “science here intrigues the industry.”<stembedurl>https://stocktwits.com/MiltonMilkyMilkovich/message/641313031</stembedurl><a href="https://stocktwits.com/symbol/IBIO">IBIO stock</a> is up 22% year-to-date, but down 14% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/what-is-fueling-smr-stock-surge-today/cmU2QIKR4dB">What Is Fueling SMR Stock's Surge Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

IBIO Stock Soars 12% Pre-Market After Company Announces $26 Million Private Placement

iBio stated that it is selling more than 11 million shares of its common stock at a purchase price of $2.35 apiece.

Equity

Best Penny Stocks To Consider - December 10th

iBio, iBio, Momentus, Bitfarms, Richtech Robotics, Bit Digital, and Strive are the seven Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced shares...

Top Manufacturing Stocks To Keep An Eye On - December 10th

Taiwan Semiconductor Manufacturing, Applied Materials, Johnson Controls International, Flex, iBio, FREYR Battery, and Fabrinet are the seven Manufacturing stocks to watch today, according to...

Manufacturing Stocks To Research - December 8th

Taiwan Semiconductor Manufacturing, Applied Materials, Flex, Johnson Controls International, and iBio are the five Manufacturing stocks to watch today, according to MarketBeat's stock screener tool...

Best Biotech Stocks To Keep An Eye On - December 8th

WAVE Life Sciences, Vertex Pharmaceuticals, iBio, argenex, and Cidara Therapeutics are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares...

iBio, Inc. (IBIO) Reports Q1 Loss

iBio (IBIO) delivered earnings and revenue surprises of -57.14% and 0.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of iBio, Inc.(IBIO) were in the spotlight on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/04/07/3056559/0/en/iBio-Announces-IBIO-600-Non-Human-Primate-Data-Showing-Extended-Half-Life-and-Muscle-Growth-and-Interim-In-Vivo-Results-for-First-in-Class-Activin-E-Antibody-Advancing-Cardiometabo.html">announced</a> positive data from a study conducted in animals for its lead asset IBIO-600.The company said data from a study on elderly and obese non-human primates shows that the anti-myostatin antibody could provide a weight loss treatment option while preserving and promoting muscle growth.The study consisted of a single administration of two dose levels: 5mg/kg and a high dose of 50mg/kg.Shares of the company were down by over 43% on Monday noon amid a broader market decline.Notably, the study does not prove statistical significance and only involves a single administration of the antibody.However, the study demonstrated an extended half-life for the antibody, potentially enabling a once three to six-month dosing schedule in humans, the company said.CEO Martin Brenner said the company is on track for a regulatory submission for the antibody in the first quarter (Q1) of 2026.iBio in-licensed IBIO-600 from AstralBio, Inc. in January. The company paid AstralBio $750,000 by issuing its common stock as an upfront payment and said AstralBio will also be eligible for development and commercialization milestone payments totaling up to $28 million.On Monday, the company also announced preclinical data for an Activin E antibody and said that the antibody showed positive results in an exploratory study with obese mice, highlighting its potential as a treatment for obesity.On Stocktwits, retail sentiment about iBio remained in the ‘bearish’ territory while message volume rose marginally within ‘low’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:654/152;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_07_at_11_29_58_AM_png_24aaec3e9f.webp" alt="IBIO's Sentiment Meter and Message Volume as of 11:30 a.m. ET on April 7, 2025 | Source: Stocktwits" width="654" height="152"><figcaption>IBIO's Sentiment Meter and Message Volume as of 11:30 a.m. ET on April 7, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed surprise at the stock’s downward trajectory.<stembedurl>https://stocktwits.com/Skypier2/message/610731384</stembedurl>Another opined that the company needs to protect itself against any potential hostile takeovers.<stembedurl>https://stocktwits.com/dcpanda/message/610733604</stembedurl><a href="https://stocktwits.com/symbol/IBIO">iBio shares</a> are down by over 24% this year and by over 19% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/federal-reserve-board-of-governors-will-meet-today/chf1DjqRb7o">Federal Reserve Board Of Governors Will Meet Today — Traders Factor In 4 Rate Cuts This Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

iBio Stock Plummets Despite Positive Data On Weight-Loss Treatment Antibody: Retail Stays Bearish

However, the company said that the study does not prove statistical significance and only involves a single administration of the antibody. 

Biotechs have underperformed the broader market this year, and these stock are at crossroads as they await the new administration under Donald Trump to take over shortly after the new year.The SPDR S&amp;P Biotech ETF ($XBI) has gained 9.2% for the year-to-date period compared to the 25%+ gain for the S&amp;P 500 Index. The iShares Biotechnology ETF ($IBB), which has a relatively higher proportion of mid- and large-cap stocks, has also added under 10% so far this year.The underperformance takes away the sheen of the industry’s defensive credentials.&nbsp;R&amp;D momentum slowed during the year, as is evident from the new molecular entity approvals, which number 38 so far this year compared to 47 for the same period last year.&nbsp;&nbsp;Most biotech companies operate deep in the red for a very long time until they could begin commercializing products. They rely on debt financing which came to be expensive in an elevated interest rate environment.&nbsp;With a change of guard on the political arena following Trump's win, the outlook for the industry is yet unclear.Morgan Stanley Head of Policy Monica Guerra&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.morganstanley.com/articles/trump-re-election-implications-for-markets">said&nbsp;</a>in a recent note that deregulation is likely to be a major theme expected during the second term. “Less stringent requirements in pharmaceuticals and biotechnology, meanwhile, could help those industries by prompting accelerated drug approvals,” she said.BMO Capital Markets analyst Evan Seigerman said the election results are “modestly positive” for the biopharma sector,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fiercepharma.com/pharma/trump-white-house-again-whats-ahead-pharma">according</a> to FiercePharma. The analyst sees potential deprioritization of the Internal Revenue Service, likely less Federal Trade Commission interference, and lower corporate taxes.Jefferies analysts does not expect the proposed drug pricing reforms to pass as the Republican legislators are divided over the proposals.Amid the ongoing discussions about the implications of Trump’s presidency, here’s a few biopharma stocks that are on retail’s radar (based on the number of followers on the Stocktwits platform):Moderna, Inc. ($ MRNA): 107,109 watchersNovavax, Inc. ($NVAX): 101,846Pfizer, Inc. ($PFE): 99,425 watchersiBio, Inc. ($IBIO): 93,617 watchersInovia Pharma, Inc. ($INO): 93,414 watchersJaguar Health ($JAGX): 81,859 watchersGilead Sciences, Inc. ($GILD): 77,094 watchersVaxart, Inc. ($VXRT): 75,807 watchersTonix Pharmaceutical Holding Corp. ($TNXP): 72,666 watchersSorrento Therapeutics, Inc. ($SRNE): 68,474 watchersRead Next:&nbsp; <a href="https://stocktwits.com/news-articles/markets/equity/block-ceo-jack-dorsey-weighs-in-on-election-impact/cJ4EMJ3Raj">Block CEO Jack Dorsey Keeps Fingers Crossed Over Regulatory Environment As Trump Makes A Comeback</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

GOP lawmakers are divided over drug pricing reforms.

Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

iBio Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

IBIO
iBio Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IBIO News

IBIOiBio Inc